Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD‑98059 is a synthetic small molecule that acts as a potent and selective inhibitor of mitogen‑activated protein kinase kinases (MAPKK), specifically MEK1 and, to a lesser extent, MEK2. It binds to the inactive form of MEK1/MEK2 and prevents their activation by upstream kinases such as c-Raf. This inhibition blocks the phosphorylation and subsequent activation of MAP kinase (ERK), thereby suppressing downstream signaling in the MAP kinase cascade. PD‑98059 is widely used in research to dissect MAPK pathway functions, including studies on cell proliferation, differentiation, apoptosis, immune responses, and cancer biology. It has demonstrated antiproliferative effects in various cell lines but is not approved for clinical use[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PD-98059.